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Since 1995, when the concept of oligometastatic non-small cell lung cancer 
was first described, no high-level evidence has been introduced for management 
of those patients subset. Data from retrospective reports and analysis and from 
every-day clinical practice revealed that some of the non-small cell lung cancer 
patients with a few metastases could benefit significantly with local radical treat-
ment approach of primary and metastatic lesions. Recent advances in modern 
local treatment approaches with minimally invasive surgery and stereotactic 
radiotherapy, as well as introduction of immunotherapy, open new field of interest 
for personalized treatment of limited metastatic non-small cell lung cancer. In this 
report, we are summarizing limited data of case reports, retrospective studies and 
few randomized studies of patients with oligometastatic non-small cell lung cancer 
and discuss challenges of treatment in the era of molecular targeted therapy and 
immunotherapy.
Keywords: oligometastases, non-small cell lung cancer, ablative treatment, 
stereotactic body radiation therapy, immunotherapy, molecular targeted therapy
1. Introduction
Lung cancer is the leading cause of cancer mortality worldwide, with over 1.7 
million deaths and over 2 million newly diagnosed cases annually [1]. More than 
a half of all new diagnosed patients with non-small cell lung cancer (NSCLC) 
presents in stage IV disease with a median overall survival (OS) of 10–12 months. 
Stage IV NSCLC is generally considered incurable disease with a 5-year survival 
ranged from 0 to 10% [2]. However, the sub segment of patients in stage IV was 
recognized years ago with different clinical presentation and prolonged survival 
that overcomes expected for metastatic disease [3]. Oligometastatic disease was first 
described in 1995 as a state of limited systemic metastatic burden in which treat-
ment of oligometastases with radical local therapies could be curative in selected 
patients [3, 4]. For decades, no high-level evidence has been introduced for manage-
ment of these patients subset. Moreover, no uniform definition and staging require-
ments for usage the term oligometastatic NSCLC have been accepted until recently. 
Clinical data indicate that the number of patients with oligometastatic disease that 
undergo ablative local treatment is increasing at a great rate [5]. With the exten-
sion of imaging diagnostic methods like 2-deoxy-2-[fluorine-18]fluoro-D-glucose 
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positron emission tomography/computed tomography (18F-FDG PET/CT) and 
magnetic resonance imaging (MRI), oligometastatic NSCLC patients who benefit 
most from radical treatment could be selected precisely [6]. On the other hand, 
development in technical improvement of modern local treatment approaches and 
advances in new systemic treatment options for NSCLC patients offer new hope for 
improvement of outcomes in oligometastatic NSCLC. In this chapter, we present 
most relevant scientific evidence regarding oligometastatic NSCLC and discuss 
future perspectives in treatment of these patients in the era of molecular targeted 
treatment and immunotherapy.
2. Definition
Even the oligometastatic disease was first described in 1995, no uniform and 
clear definition has been accepted for years [3]. Most past clinical trial protocols 
have used an upper limit of metastases between one and eight as inclusion criteria; 
however, 90% of included patients actually had one metastasis [5, 7].
The concept of oligometastatic NSCLC include different clinical scenarios 
of limited number of metastatic lesions that are feasible to local ablative treat-
ment. Regarding the time of presentation, in synchronous oligometastatic disease 
metastatic lesions are detected at the time of diagnosis of the primary tumor. In 
metachronous oligometastatic disease new metastatic lesions not present at the time 
of the primary diagnosis develop [8, 9]. Other related terms are currently used, like 
oligorecurrence, in which limited number of metastatic lesions develop in other-
wise controlled primary tumor site followed radical treatment. Oligoprogression 
describes metastatic disease with controlled primary tumor and most metastases 
due to systemic therapy followed by progression of one or few metastatic lesions. 
Oligoressistance follows systemic therapy of patients with widespread metasta-
ses who have a near complete response but limited number of persistent lesions 
remains. First attempt to unify the oligometastatic state was inclusion oligometa-
static disease in the 8th edition of the Tumor, Node, Metastasis (TNM) published by 
the International Association for the Study of Lung Cancer (IASLC). In the assess-
ment for M descriptor, 225 (22%) of the 1025 metastatic patients were reported 
with a single metastasis in a single organ that had significantly better prognosis 
than those with multiple metastases in one or several organs [10]. Accordingly, 
single metastatic lesion in a single distant organ was assigned to the new M1b 
category [2, 10].
Recently, a pan-European multidisciplinary consensus statement on the definition 
and staging of synchronous oligometastatic NSCLC was formulated [11]. As it was 
concluded, the definition is relevant when a radical treatment is technically feasible 
with acceptable toxicity, with all sites being amenable to local treatment modality that 
may result in long-term disease control. A maximum of 5 metastases and 3 organs is 
proposed for definition of oligometastatic NSCLC. The presence of diffuse serosal 
metastases (meningeal, pericardial, pleural, and mesenteric) or bone marrow involve-
ment excludes cases from the definition, as these cannot be treated with radical 
intent. For pulmonary metastases, the eight TNM classification should be followed. 
Metastasis in the same lobe (T3) or in the same lung (T4) should not be counted as 
a metastatic site, but it can influence the possibility of treatment with radical intent. 
Mediastinal lymph nodes must be considered as regional disease, but their involve-
ments are of importance in the decision of feasibility for radical treatment of locore-
gional disease. The recommendations for staging include 18F-FDG PET/CT and brain 
imaging, preferably magnetic resonance imaging (MRI), that are mandatory. Besides 
mediastinal lymph node staging with 18F-FDG PET/CT, pathological confirmation is 
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required if this influences the treatment decision. In addition, pathological confirma-
tion at least of one metastasis is required unless the risk outweighs the benefit.
3. Incidence
Oligometastatic disease used to be reported sporadically [12]; however, with the 
improvement in diagnostic imaging, mainly 18F-FDG PET/CT and MRI, oligometas-
tases appear relatively frequent. While available data on incidence of oligometastatic 
NSCLC at diagnosis remains limited, even when published mostly in retrospective 
reports, the diversity of inclusion criteria about the maximum number of metastatic 
lesions accepted for study, makes it more difficult to compare. However, it has been 
estimated that aproximatelly 20–50% patients with metastatic NSCLC at diagnosis 
present with oligometastatic disease [10, 13, 14]. As mentioned before, in the 
IASLC TNM classification of lung cancer, 22% of all metastatic patients had a single 
metastatic lesion [10]. The most frequent site of a single lesion was bone, followed by 
brain, adrenals and liver. In an analysis of 725 NSCLC patients with metastatic dis-
ease at diagnosis, 186 (26%) were recognized with oligometastatic disease defined 
as ≤5 lesions [13]. Of those, 51% of the patients had a single metastatic lesion and in 
81% of patients, metastases were limited to one organ site. As in previous analysis, 
the most common site of a single lesion appearance was brain, bone and adrenal 
glands. In the group of oligorecurrent NSCLC patients after treatment of the pri-
mary site, 50–60% were reported to present with only one to three metastatic sites 
[4, 15]. The majority of patients who have been treated with surgery, at recurrence 
presented with metastases in the brain, contralateral lung or adrenal gland. The 
pattern of oligoprogression in advanced or metastatic NSCLC patients after first-line 
chemotherapy has been barely reported. In a study of Rusthoven et al., local progres-
sion only, was the predominant pattern of failure in 64% of patients after systemic 
therapy, mostly platinum-based chemotherapy, suggesting that consolidation local 
therapy after first-line systemic treatment could potentially alter the patterns of 
failure and prolong time to progression in a substantial proportion of those patients 
[14]. With the introduction of new systemic treatment possibilities that prolong 
survival, like tyrosine kinase inhibitors (TKI) in patients with epidermal growth fac-
tor receptor (EGFR) mutation/anaplastic lymphoma kinase (ALK) rearrangement, 
oligoprogression has been reported more often. Molecular targeted therapy with TKI 
enable higher response rates and better progression-free survival (PFS), however, 
progression inevitably develops in most cases after 1 to 2 years of molecular targeted 
treatment due to acquired resistance [16]. Data from literature reveals that the 
proportion of patients progressing with an oligoprogressive pattern of disease ranges 
from 15 to 47% during EGFR TKI treatment [17–19]. Few series also suggest that as 
many as 25% of patient treated with TKI progress with single metastases and 50% 
with four or less lesions [17, 20]. For those patients with oligoprogressive or oligo-
resistance disease, local ablative therapy and continuation of molecular targeted 
therapy could result in more than 6 months of additional clinical benefits [20].
4. Prognostic factors
Oligometastatic disease is highly divers in prognosis, ranged from rapid progres-
sion with demise during treatment to long-term survivals. It is assumed that about 
25% of oligometastatic patients will have prolonged disease-free interval [7, 12, 21]. 
Therefore, the identification of oligometastatic patients that will benefit most from 
aggressive local treatment is of the crucial importance.
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As already mentioned, results from IASLC 8th TNM classification validation 
study revealed significantly longer OS in patients with a single extrathoracic metas-
tasis than in those with multiple metastases [10]. In the individual patients data 
meta-analysis of Ashworth et al. 757 oligometastatic NSCLC patients were included 
from 1985 to 2012 and managed with ablative treatments to all sites of disease, 
however, half of the patients had only a single metastasis [7]. Surgery was the most 
commonly used treatment for the primary tumor (83.9%) and metastases (62.3%). 
Factors predictive for OS were synchronous versus metachronous metastases 
(P < .001), N-stage (P = .002), and adenocarcinoma histology (P = .036). In recur-
sive partitioning analysis, three risk groups were identified: low-risk, metachronous 
metastases (5-year OS, 47.8%); intermediate risk, synchronous metastases and 
N0 disease (5-year OS, 36.2%); and high risk, synchronous metastases and N1/N2 
disease (5-year OS, 13.8%). In the analysis of Parikh et al., 186 patients with five or 
fewer distant metastatic lesions at diagnosis were included, of whom 52% patients 
had a single metastatic lesion [13]. On multivariable analysis, Eastern Cooperate 
Oncology Group (ECOG PS) performance status, nodal status N2–3, squamous 
pathology, and metastases to multiple organs were associated with a greater hazard 
of death (all P < .01). However, the number of metastatic lesions and radiologic 
size of the primary tumor were not associated with OS. Definitive local therapy to 
the primary tumor was associated with prolonged survival. Data from twenty-four 
studies that included altogether 1935 patients with oligometastatic NSCLC were 
analyzed in a meta-analysis by Li et al. [22]. Among patients with oligometastatic 
disease, defined as 5 or fewer lesions, they identified several factors associated 
with improved survival, including aggressive treatment to the primary lung tumor, 
female gender, lower nodal stage, adenocarcinoma histology and thoracic stage. 
Other retrospective publications reported importance of aggressive local treatment 
[23, 24]; moreover, the major predictors of OS were the extent of intra-thoracic 
disease including nodal status and possibilities for resection or radical radiotherapy 
[25–27]. In the trial by Gomez et al. besides treatment type (local treatment versus 
no local treatment) presence of driver mutations were associated with improved 
PFS [28, 29]. Aside of the number of metastases, mediastinal node involvement, 
time until onset of metastases, histology, PS, T stage, treatment of the primary and 
metastatic lesions, diagnosis-specific graded prognostic assessment (DS-GPA clas-
sification, and Lung-molGPA) is well known for patients with brain metastasis.
Additionally, a specific genetic or epigenetic alterations (“initiation,” “progres-
sion,” and “virulence” genes) have been described so far that together with failures 
in immunosurveillance impact patients‘clinical outcomes. The oligometastatic 
tumors are believed to have more indolent biology [3]. Initial investigations of 
the mechanisms running occurrence of oligometastases identified a central role 
of microRNAs (miRNAs). Lussier and colleagues evaluated miRNA profiles in an 
analysis of patients with five metastases manageable for RT. They found that over-
expression of the miR-200 family was correlated with polymetastatic progression 
[30]. Moreover, they observed a specific microRNA expression that identified the 
patients most likely to remain oligometastatic after metastases directed treatment 
and therefore associated with a better prognosis.
5. Treatment
Since oligometastatic NSCLC is considered as intermediate state between local-
ized lung cancer and widespread metastatic disease, the therapeutic approaches 
used for treatment of these patients besides standard systemic therapy include 
aggressive local therapy.
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Several early case and retrospective reports showed that a subset of NSCLC 
patients with mostly solitary metastasis that were radically treated to all known 
metastatic sites, could achieve long-term survival [31–33]. Following years, more 
retrospective reports of oligometastatic patients treated with radical intent were 
published that demonstrating better-than-expected prolonged survival with 
median OS between 13.5 to 26 months and 5-year survival between 10 to 36% [13, 
23–25, 34–37]. In an individual patient data meta-analysis on 757 oligometastatic 
NSCLC treated between 1985 and 2012 with surgical metastasectomy, stereotactic 
radiotherapy/radiosurgery, or radical external-beam radiotherapy for metastases 
and with curative treatment of the primary lung cancer, median OS was 26 months, 
1-year OS 70.2%, and 5-year OS 29.4% [7].
While the last decade use of effective local treatment with minimally invasive 
surgery or advanced radiation technics for oligometastatic lesions in NSCLC 
patients has risen, the evidence from prospective studies has been lacking. The 
first prospective single-arm phase II trial of oligometastatic NSCLC patient with 
up to five metastases at primary diagnosis amendable for radical local treatment 
was published in 2012 [27]. Forty patients were enrolled with brain, bone and 
adrenal gland metastases. Of all included, 87% had a single metastatic lesion and 
95% of all received chemotherapy as part of their primary treatment. Median OS 
was 13.5 months and two- and three- year survival rates were 23.3% and 17.5%, 
respectively. In 2016, Gomez et al. published the results of a prospective multicentre 
randomized phase 2 trial that enrolled 74 oligometastatic NSCLC patients with 
the maximum of 3 metastatic lesion [28]. All patients received standard first-line 
systemic therapy including platinum-based chemotherapy or TKI in patients with 
EGFR mutations or ALK rearrangements. Patients were randomly assigned to either 
local consolidative therapy consisting of resection or (chemo) radiotherapy or to 
maintenance treatment alone. The study was terminated early after randomization 
of 49 patients as part of the annual analyses due to substantial efficacy improve-
ment in the local consolidative group compared with the maintenance group. At a 
median follow-up time of 12.39 months, the median PFS in the consolidative group 
was significantly longer with 11.9 months versus 3.9 months in the maintenance 
group. Importantly, time to appearance of a new lesion was longer in the consolida-
tive group arm (11.9 months vs. 5.7 months) suggesting that local consolidative 
treatment may have altered the natural course of the disease, either by limiting the 
potential for subsequent dissemination or by altering systemic anticancer immune 
response. In 2018, the updated survival data at a median follow-up of 38.8 month, 
confirmed the PFS benefit in consolidative group with 14.2 months compared to 
4.4 months in the maintenance group and median OS of 41.2 months in the consoli-
dative arm versus 17.0 months in the maintenance arm [29].
In a phase II randomized clinical trial conducted by Iyengar et al., a total of 
29 patients with oligometastatic NSCLC were included [38]. Inclusion criteria 
allowed up to six sites of extra cranial lesions (including primary) and exclude 
patients receiving first-line molecular targeted therapy with EGFR/ALK TKI. 
Fourteen patients were assign to the stereotactic body radiation therapy (SBRT)-
plus-maintenance chemotherapy arm, and 15 patients to the maintenance che-
motherapy–alone arm. In the SBRT group, all residual disease sites were treated 
with SBRT. A total of 31 lesions were treated in 14 patients with intrathoracic sites 
the most common locations of SBRT treatment. Likewise, the trial was stopped to 
accrual early after an interim analysis found a significant improvement in PFS in the 
SBRT-plus-maintenance chemotherapy arm with 9.7 months vs. 3.5 months in the 
maintenance chemotherapy–alone arm (P = .01).
A third completed randomized phase II trial, SABR (stereotactic ablative 
radiotherapy)-COMET international trial included patients with a controlled 
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primary malignancy of different solid cancers and 1–5 metastatic lesions manage-
able for SABR treated between 2012 and 2016 [39]. Ninety-nine patients, of those 
18% NSCLC patients, were randomly assigned in a 1:2 ratio between standard-
of-care treatments and standard-of-care treatments plus SABR. Median OS was 
28 months in the control group versus 41 months in the SABR group. Adverse events 
of grade 2 or worse were significantly higher in SABR group (29% vs. 9%) with 
three deaths after SABR. Recently, results of extended follow-up were published 
[40]. With the median follow-up of 51 months, median OS was 28 months in the 
control arm versus 50 months in the SABR group. Five-year OS rates were 17.7% 
versus 42.3%, respectively. There were no new grade 2–5 adverse events.
All three randomized studies have contributed increasingly in the evidence that 
radical local treatment approach added to standard therapy may yield prolonged 
survival in selected oligometastatic NSCLC. However, last decade most studies have 
still been retrospective in nature and biased with respect to definition of oligometa-
static disease. Systematic review by Schanne et al. included 54 studies that were 
published between 1987 and 2018 with altogether 1994 patients with oligometastatic 
NSCLC [5]. Even with a wide range of oligometastatic definitions, 90% of patients 
were treated for a single metastasis. 60% of patients were diagnosed with adenocar-
cinoma and 55% of the metastases were located in the brain, 17% in the lung, 11% 
in the adrenal gland and 17% in other organs. Systemic therapy was used in 68% of 
patients in a variety of settings, mostly adjuvant/maintenance or neoadjuvant but 
also combined with RT. Molecular targeted therapy was used in 5% of cases; how-
ever, immunotherapy was not used treatment modality in any of analyzed studies. 
Surgical resection was the most common local treatment modality used in 76% of 
patients for primary tumor and in 65% of patients for distant metastases. RT was 
used as neoadjuvant/adjuvant or definitive treatment of primary tumor in 9% and 
22%, respectively. Adjuvant RT after surgical resection for metastatic lesions was 
used in 27% of patients, mostly after resection of brain metastases. Radiation as 
primary treatment modality was more common for treatment of metastases than for 
primary tumors (69% vs. 35%). Median OS in the analyzed studies was 19.6 months 
(6.2–52.9 months) with an observed plateau and possible long-term survival of 20%. 
Importantly, this analysis also gives us insight in time trends of management oligo-
metastatic NSCLC patients for the last three decades. Relating to time analysis, in the 
studies published after 2011 radiotherapy has almost surpassed surgical approaches. 
Local treatment changed in favor to wider use of radiotherapy for primary tumors 
from 23 to 41%. Moreover, wider adoption of SBRT instead of conventionally 
fractionated RT with an increase from 0 to 23% for primary tumors and from 15 
to 60% for distant metastases was reported. Additionally, the number of patients 
receiving no systemic therapies was reduced from 45% before 2011 to 24% after-
wards. Notably, a trend for improved median OS over time was observed: patients 
from reports published after 2011 revealed better OS compared to the earlier period: 
28.1 months versus 17.2 months, respectively. Comparing the effect of different type 
of local treatment, when only studies after 2011 were included, no significant effect 
on median OS was detected neither for primary tumor nor for metastases.
Despite the lack of evidence for optimal treatment of patients with oligometa-
static NSCLC, the concept of delivering local radical treatment in patients with 
oligometastatic NSCLC was incorporated in NSCLC guidelines. The European 
Society for Medical Oncology (ESMO) Clinical Practice Guidelines due to the 
limited available evidence propose preferred inclusion in clinical trials [41, 42]. The 
National Comprehensive Cancer Network (NCCN) guidelines state that patients 
with NSCLC with limited metastases can receive local radical treatment [43].
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6. Challenges in the era of molecular targeted and immunotherapy
The management of oligometastatic NSCLC has changed significantly over the 
past decades. While surgery, radiotherapy, stereotactic radiotherapy and systemic 
therapy are the cornerstones of current treatment strategies, treatment modalities 
have varied over time with respect to the advantages of local treatment techniques 
as introduction of new systemic treatment possibilities. According to the literature, 
surgery has been mostly used in oligometastatic NSCLC patients for resection of 
brain, contralateral lung and adrenal gland metastases [5, 23, 35, 44] Considering 
the significant morbidity associated with surgical resection of multiple sites of 
metastatic disease, SBRT has become an alternative treatment approach for achiev-
ing local ablation. The highest level of evidence for incorporation of local treatment 
in oligometastatic NSCLC patients based on small randomize phase II clinical trials, 
which regularly reported higher PFS and OS with the use of SBRT compared with 
no SBRT [28, 29, 38–40]. However, the efficacy of SBRT in potentially curable 
patients with the stage I NSCLC is already confirmed [45]. The broader adoption 
of SBRT in clinical practice reflects its non-invasive nature, ability to simultane-
ous treatment of multiple sites in a short time, feasibility of concurrent local and 
systemic treatment, utility to treatment in the outpatient setting and relatively 
low toxicity profile [46, 47]. Moreover, SBRT to the progressing lesions may delay 
the need to start or change systemic therapy that might reflect in prolonged PFS, 
OS and quality of life for the patients [48–50]. In a systematic review by Tsao 
et al., reported median OS ranged from 13.5 to 55 months and PFS from 4.4 to 
14.7 months. [50] SBRT has currently become a treatment option for tumors in 
almost any body site, with many publications documenting its efficacy for lung, 
liver, adrenal, and bone/spine metastases, achieving high as much as 70–90% of 
local control [51].
Systemic therapy is the backbone treatment for metastatic NSCLC patients; 
though it is not well defined in management for oligometastatic NSCLC [41–43]. 
Despite potentially successful local treatment, the majority of oligometastatic 
NSCLC patients will develop distant progression due to undetectable microme-
tastases at the time of diagnosis. Therefore, all recent prospective trials combined 
local treatment with addition of systemic therapy standardly used at the time of the 
study. However, the therapeutic sequence of systemic therapy might be important 
for oligometastatic disease, as usually only the patients who do not progress with 
induction systemic treatment were capable for aggressive local treatment. We are 
currently not able to reliably predict the course of oligometastatic disease at the 
time of diagnosis, therefore upfront local therapy colud represent an overtreatment 
due to rapid progression to multimetastatic disease. Although studies with oligo-
metastatic NSCLC have included patients treated with systemic therapy, mostly 
chemotherapy and minority molecular targeted therapies, current clinical practice 
and guidelines for treatment of metastatic NSCLC include molecular targeted 
agents, immunotherapy or combination of immunotherapy and chemotherapy in 
first-line setting [52–64]. The introduction of new agents as molecular targeted and 
immunotherapy has resulted in the improved survival in patients with metastatic 
and locally advanced NSCLC. As a result, the first line systemic therapies used in 
most retrospective and prospective studies of oligometastatic NSCLC do not reflect 
those currently used. With onset of new systemic therapies in the management 
of NSCLC patients, great interest has risen in exploring the safety and efficacy of 
combined SBRT with new agents to improve the therapeutic outcomes in metastatic 
NSCLC as well as in oligometastatic disease.
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6.1 Molecular targeted therapy in oligometastatic NSCLC
Patients with actionable tumor mutations have high response rates and long PFS 
times when treated with molecular targeted therapy [54–62]. However, progression 
inevitably occurs due to either insufficient CNS passage of the drug in some cases 
of CNS progression, or to acquired resistance with biological change in the tumor 
cells. The concept of oligoprogression supports the idea of disease progression due 
to the development of TKI-resistant clones with subsequent distant progression 
[65]. Different scenarios of progression in patients with actionable tumor muta-
tions including oligoressistance, oligoreccurence or oligoprogression requiring 
consideration for local treatment. In the analysis of Guo et al. the majority of 
progressive disease on osimertinib was reported within residual lesions in initially 
involved sites, thus consolidative SBRT may prolong time to progression in a 
selected subgroup of patients [66]. In a retrospective study of Xu et al., 145 patients 
with oligometastatic EGFR-mutant NSCLC diagnosed from 2010 to 2016 were 
enrolled [67]. According to consolidative local treatment with surgery or radio-
therapy, patients were grouped in three category, 51 in the all-local therapy group 
(consolidative to all residual disease, including primary tumor, lymph nodes, and 
metastatic sites), 55 in the part-local therapy group (consolidative to either primary 
tumor or oligometastatic sites), and 39 in the non-local therapy group (not receive 
any local therapy). Radiotherapy included standard-fractionation radiotherapy 
(60 Gy in 2-Gy fractions), aggressive palliation radiotherapy (45 Gy in 3-Gy frac-
tions, a biologically equivalent dose of approximately 60 Gy) or stereotactic radio-
surgery (SRS), with curative intent when possible. The median PFS in all-local, 
part-local, and non-local groups were 20.6, 15.6, and 13.9 months, respectively 
(p < 0.001). The median OS in all-local, part-local, and non-local groups were 40.9, 
34.1, and 30.8 months, respectively (p < 0.001). The difference was significant 
between the all-local group and part-local or non-local group. The median OS was 
significantly better with consolidative local therapy for primary tumor (40.5 versus 
31.5 months, p < 0.001), brain metastases (38.2 versus 29.2 months, p < 0.002), 
and adrenal metastases (37.1 versus 29.2 months, p < 0.032). Radiation toxicity 
was acceptable, included grade ≥ 3 pneumonitis (7.7%) and esophagitis (16.9%). 
No grade 5 toxicity was reported. A retrospective multi-institutional analysis by 
Magnuson et al. explored the optimal management of patients with EGFR-mutant 
NSCLC who developed brain metastases and have not received EGFR TKI [68]. 
A total of 351 patients from six institutions were included. Patients were treated 
with SRS followed by EGFR-TKI, WBRT followed by EGFR-TKI, or EGFR-TKI 
followed by SRS or WBRT at intracranial progression. The median OS for the SRS, 
WBRT, and EGFR-TKI cohorts was 46, 30 and 25 months, respectively (P < .001). 
On multivariable analysis, SRS versus EGFR-TKI, WBRT versus EGFR-TKI, age, 
performance status, EGFR exon 19 mutation, and absence of extracranial metas-
tases were associated with improved OS. SRS followed by EGFR-TKI resulted in 
the longest OS and allowed patients to avoid the potential neurocognitive sequelae 
of WBRT.
In a retrospective analysis of Elamin et al. 129 patients with EGFR-mutant 
NSCLC who were treated with first-line TKI and 12 that were treated with TKI 
followed by local consolidation therapy were included [69]. Among the 12 patients 
treated with TKI plus local consolidative treatment, 8 patients had oligometa-
static disease (defined as 3 metastases), and 4 patients had >3 metastases. Local 
consolidative treatment regimens were hypofractionated radiotherapy or SBRT 
for 11 patients and surgery for 1 patient. TKI followed by local consolidative treat-
ment resulted in a significantly longer PFS (36 months) compared with TKI alone 
(14 months). Recently, Wang et al. presented an interim result of a randomized 
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phase III, open-label clinical trial of first-line tyrosine kinase inhibitor with or 
without upfront local RT in patients with EGFR oligometastatic NSCLC [70]. From 
January 2016 to January 2019, 133 participants were enrolled, including 65 in the 
TKI arm who received standard of care TKI alone and 68 in the SBRT arm who 
received SBRT and TKI. At a median follow-up of 19.6 months, the median PFS for 
TKI alone was 12.5 months, and for TKI and SBRT was 20.20 months, respectively 
(P < .001). The median OS in the TKI alone arm was 17.40 months, and for TKI and 
SBRT arm was 25.50 months, respectively (P < .001).
Concerning the safety profile for combining EGFR or ALK TKI inhibitors 
and high dose RT, treatment was well tolerated and none of the available studies 
reported a significant increase in side effects [66–69]. To conclude, SBRT in com-
bination with molecular targeted agents in actionable mutations NSCLC patients 
seem rationale for improving long-lasting disease control in synchronous oligo-
metastatic oncogene addicted NSCLC patients; however no prospective data are 
available to confirm this.
6.2 Combining immunotherapy and radiotherapy
Immunotherapy with immune checkpoint inhibitors has revolutionized the 
management of stage IV NSCLC. In recent years, the blockade of programmed cell 
death 1 (PD-1) / programmed cell death ligand 1 (PD-L1) axis which served as a 
mechanism for tumor evasion of host tumor antigen-specific T-cell immunity, has 
demonstrated evident benefit in PFS and OS in metastatic and locally advanced 
NSCLC [61–64, 71, 72]. The indications for PD-1/PD-L1 blockade with immune 
checkpoint inhibitors (ICI) currently include most metastatic NSCLC patients 
without actionable tumor mutations, either as a single agent or combined with 
cytotoxic chemotherapy. The anti-PD-1/PD-L1 drugs approved at the moment for 
NSCLC are pembrolizumab, nivolumab, atezolizumab and durvalumab. Despite 
this paradigm shift, most patients present some kind of resistance to ICI, there-
fore arise the interest of researchers to combine multiple therapies. According to 
growing preclinical data describing mechanistic synergy between radiotherapy 
and immunotherapy, the most promising investigated combination is ICI with RT 
[73, 74]. Rational for combining radiotherapy and immunotherapy arises from the 
significant immune-stimulatory effects they both possess increasing the natural 
antitumor immune response through synergistic potentiation of an immuno-
modulatory effect [75, 76]. Increasing evidence indicates that cancer cells killed 
by radiation release tumor-associated antigens and immunoregulatory cytokines 
that serve as a kind of in situ vaccine against cancer [77, 78]. Cytokines also activate 
systemic tumor-specific immune response to eliminate tumor cells even outside 
the radiation field, so called abscopal effect [79]. This radiation-induced immune-
mediated systemic antitumor phenomenon has high therapeutic potential, but is 
rare and relating to preclinical data more probable induced by high ablative doses, 
combined with checkpoint inhibitors [80, 81]. SBRT, through released neo-antigens 
and consequent maturation and proliferation of naive T-cells, and immunotherapy 
through activation and amplification of naive T-cells, may reciprocally potentiate 
each other amplification of T-cells-mediated tumoricidal effects [82–84]. Due to the 
lack of evidence, most “immunogenic” time sequencing of radio-immunotherapy 
and radiation dose-fractionation is not determined. Some data indicate that concur-
rent treatment or close sequencing of immunotherapy following radiotherapy may 
be the most effective [82]. However, according to data the radiation dose for the 
optimal antitumor immune response should be sub-tumoricidal. Several preclinical 
studies suggested that 8 to 10 Gy per fraction in 1–3 fractions represent optimal 
immunogenic dose [82–84].
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Clinical interest for the combination of ICI and RT in NSCLC started to arise 
after the results of the KEYNOTE-001 study that enrolled progressive locally 
advanced or metastatic NSCLC [85]. A secondary analysis of the phase I trial 
revealed that of 97 included patients, 43% had been treated with RT prior to the 
administration of pembrolizumab. Those patients had significantly longer PFS 
(4.4 vs. 2.1 months) and OS (11.6 vs. 5.3 months) comparing patients with no RT. 
A single-arm phase 2 study of Bauml et al. included 45 patients with oligometa-
static NSCLC with up to 4 metastatic sites [86]. Pembrolizumab was administered 
4 to 12 weeks after prior comprehensive locally ablative therapy consisting of 
radiotherapy, chemoradiotherapy, surgery, or radiofrequency ablation, but most 
received ablative radiotherapy. Median PFS was 19.1 months, significantly greater 
than the historical median of 6.6 months (P = .005). OS at 12 months was 90.9% 
and at 24 months 77.5%. Even not conducted in oligometastatic NSCLC patients, 
the results of a multicetre, randomized phase 2 study (PEMBRO-RT) are interested. 
92 patients were enrolled with advanced NSCLC after at least one regiment of 
chemotherapy with at least two metastases but upper limit was not specified [87]. 
Altogether, 76 patients were randomized to the pembrolizumab alone (control, 40 
patients) or pembrolizumab after radiotherapy (3 fraction of 8 Gy) that was applied 
to a single metastatic site (experimental, 36 patients) to increase the likelihood of 
abscopal effect. The overall response rate at 12 weeks was 18% in the control arm vs. 
36% in the experimental arm (P = .07). Median PFS was 1.9 months vs. 6.6 months 
(P = .19), and median OS was 7.6 months vs. 15.9 months (P = .16). Although a 
doubling of overall response rate was observed, the results did not meet the study’s 
prespecified end point criteria for meaningful clinical benefit. Interestingly, sub-
group analyses showed the largest benefit of radiotherapy in patients with PD-L1 
– negative tumors. In a retrospective study of Samstein et al. 758 patients treated 
with ICI and RT were analyzed [88]. Median OS was 9 months in the entire cohort. 
Subanalysis regarding sequencing ICI and RT revealed increased OS in patients 
who received ICI and RT simultaneously. Median OS was 20 months for patients 
who started with ICI for at least 1 month before RT and continued throughout RT 
compared with 11 months for those that started ICI less than 30 days prior to RT 
and continued ICI throughout RT. In the cohort of patients who received concur-
rent therapy, hypofractionated radiotherapy (dose >4.00 Gy per fraction) and ICI 
greater than 30 days before RT was associated with improved OS.
Prospective data for management of patients with oligometastatic NSCLC in 
the era of immunooncology is scarce. Most of the available data on combining ICI 
and SBRT has been retrospective experiences on patients with metastatic NSCLC; 
however the benefit of combined treatment has been persistently demonstrated 
[89–91]. Importantly, the available data suggest that toxicity profile from the 
combination treatment has not increased in comparison to immunotherapy alone 
in the metastatic setting. A recent systematic review from prospective studies 
revealed grade ≥ 3 median toxicity rates of 14.5% with anti-PD-1/L1 plus SABR and 
26% with anti-CTLA-4 plus SABR [92]. Concerning toxicity, no increased rates of 
immune-related adverse events using SBRT in the different organs or tissue types 
have been reported. However, reports from the studies that combined dual ICI 
therapy with SBRT in different cancers in prospective trials detected more toxicity.
In the future management of oligometastatic NSCLC patients, more questions 
should be answered. In the era of immunooncology, local treatment still presents 
the backbone of management with adding ICI to improve outcome of oligometa-
static NSCLC patients. However, future prospective studies should give us answers 
to what sequence of local treatment and ICI is the most optimal combination, 
which radiation technique and fractionation would offer the best results, which 
patients should be selected for radical-intent treatment regarding biomarkers. 
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A great number of trials combining ICI and RT are ongoing. Regarding oligometa-
static NSCLC, one is of particular interest, a randomized trial of consolidative 
immunotherapy with vs. without thoracic radiotherapy and/or SBRT after first-
line systemic therapy for metastatic NSCLC comparing PFS as primary objective 
(NCT03867175).
7. Beyond progression: oligoprogression in NSCLC patients
An important growing subsegment of NSCLC patients is a group with oligopro-
gressive disease. With more effective systemic therapies that offer high response 
rates and long PFS times in patients with metastatic NSCLC, the oligoprogressive 
disease has become more and more common clinical scenario. Oligoprogressive 
disease, presented in oncogene driven NSCLC mostly occur due to the isolated 
emergence of well-described resistance mutations [65]. According to the literature, 
the occurrence of oligoprogression during TKI treatment seems to be quite fre-
quent, reported in the range of 32–49% [17, 19, 20]. However, the optimal therapeu-
tic approach in these patients is still unclear. Three main treatment options include 
changing systemic therapy, continuing the same systemic therapy beyond progres-
sion or using local therapy for eradicate the resistant clones while continuing the 
same systemic therapy [41]. The evidence supporting local treatment is limited to 
small retrospective reports. Weckhard et al. reported that 49% of ALK or EGFR 
positive metastatic NSCLC patients are treated with TKI presented with intracranial 
or extracranial oligoprogression suitable for local treatment [20]. Of 25 patients, 
24 were treated with RT and one underwent surgery; however, 19 of 25 locally 
treated patients progressed again with PFS of 6.2 months. Yu et al. reported on 184 
patients with EGFR mutation, of these 42 progressed with intracranial and 18 with 
extracranial oligometastases. These 18 were treated with local therapy, including 
surgery, radiofrequency ablation or RT with the median TTP of 10 months. Gan 
et al. reported on 33 ALK+NSCLC patients treated with crizotinib that had extra-
cranial oligoprogression. Of these, 14 were suitable for local treatment with SBRT. 
Median overall time on crizotinib among those treated with SBRT versus those who 
progressed but were not suitable for SBRT was 28 and 10.1 months, respectively. 
Patients remaining on crizotinib for >12 months vs. ≤12 months had a 2 year OS 
of 72% vs. 12%, respectively (p < 0.0001) [93]. Xu et al. reported on 206 EGFR-
mutant NSCLC patients included in the analysis of the survival benefit of adding 
local ablative therapy after oligoprogression during first-line TKI. With the median 
follow-up time of 42 months, the median PFS1, median PFS2 and median OS were 
10.7 months, 18.3 months and 37.4 months, respectively. Survival rates of 1 year, 
2 years and 3 years were 94.1%, 78.9%, and 54.7%, respectively. Altogether, the data 
suggest that local ablative treatment of progressive lesions in actionable mutations 
NSCLC patients can prolong treatment with first-line TKI without reported unac-
ceptable excess toxicity. Moreover, despite the paucity and the heterogeneity of 
clinical data the use of local therapy in oligoprogressive oncogene driven NSCLC is 
already considered as standard clinical practice [94].
Currently, a few prospective randomized clinical trials are ongoing researching 
the benefit of local ablative treatment in oligoprogressive NSCLC. A Canadian trial, 
the STOP-NSCLC (NCT02756793) is a randomized phase II trial with estimated 
enrolment of 54 patients with oligoprogressive NSCLC during TKI or maintenance 
chemotherapy that evaluate either SBRT with continuation of current systemic 
agents or standard of care that may include continuation of current systemic agent, 
observation or switch to next-line treatment. Primary end-point will be PFS, while 
secondary end-points will be OS, local control, toxicity, quality of life and patterns 
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of further progression. Similarly, European HALT study (NCT03256981) is a phase 
II/III, randomized study with question whether the use of SBRT to ≤3 sites of oli-
goprogressive disease in mutation positive advanced NSCLC patients with continu-
ation of TKI improves PFS compared to continuation of TKI alone. The study aims 
to recruit 110 patients with oligoprogressive mutation positive advanced NSCLC 
following initial response to TKI. Third ongoing randomized trial is PROMISE-004 
(NCT03808662) study with heterogeneous cohort including breast and NSCLC 
patients and estimated enrolment of 160 patients with either no targetable muta-
tions upfront or targetable mutations after progression on first-line TKI. The 
purpose of the study is to evaluate the role of SBRT when metastatic lesions have 
just begun to grow with PFS as primary end-point.
In the context of immunotherapy in NSCLC patients, which includes the major-
ity of lung cancer patients currently, tumor escape is not uncommon, but studies 
of oligoprogression are lacking. According to mechanism, oligoprogression might 
represent local immune tolerance due to stromal or tumor changes. Recently, in 
order to specify oligoprogression in NSCLC patients treated with immunotherapy, 
the results of a retrospective analysis of the failure pattern of 297 on ICI and 75 
patients treated combined with chemotherapy and ICI were published [95]. Under 
ICI monotherapy in the first-line treatment, oligoprogression was more frequent 
(20% vs. 10%, p < .05), occurred later (median 11 vs. 5 months, p < .01) and 
affected fewer sites (mean 1.1 vs. 1.5, p < .05) compared to oligoprogression in 
patients treated with ICI monotherapy in later lines. Lymph nodes (42%, manly 
mediastinal) and the brain (39%) were mostly affected, followed by the lung 
(24%) and other organs. Compared to multifocal progression, oligoprogression 
occurred later (11 vs. 4 months, p < .001) and was associated with longer survival 
(26 vs. 13 months, p < .001) and higher tumor PD-L1 expression (p < .001). 
Chemoimmunotherapy showed a similar incidence of oligoprogression as ICI 
monotherapy (13% vs. 11% at 2 years). Local treatments were applied regularly for 
brain but only in 50% for extracranial lesions. However, oligoprogression in NSCLC 
patients is less common under ICI treatmnet than under TKI and its frequency 
descent with time. Few prospective trials evaluate the value of RT in oligoprogres-
sive NSCLC treated with ICI, with one randomized phase II study designed to 
evaluate the effect of local consolidative RT to all sites of oligoprogressive disease 
in patients with metastatic NSCLC who have progressed through first-line systemic 
therapy containing an ICI (NCT04485026).
8. Conclusion
The number of patients with oligometastatic NSCLC has increased significantly 
over the last decade as well as the use of the locally ablative therapy to treat these 
patients. The evidence supporting this approach includes three randomized phase 
II clinical trials and substantial retrospective data; however, the inclusion criteria 
in these trials were mostly incomparable. Oligometastatic NSCLC has recently been 
defined by a consensus of multidisciplinary group of European thoracic oncology 
experts and this was the first step to unify future researching regarding diagnostic 
procedures and inclusion criteria. Recently, the therapeutic landscape of metastatic 
NSCLC has dramatically changed with the introduction of new systemic agents 
as molecular targeted and immunotherapy resulting in the prolonged survival 
and changing the field of oligometastatic framework significantly. A new concept 
that emerged with more effective systemic therapy is oligoprogression, frequently 
presents in patients treated with TKI. Additionally, combining radiotherapy 
and immunotherapy represent an increasing filed of interest due to synergistic 
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potentiation of an immunomodulatory effect as a way to overcome the resistance 
of immunotherapy that exist in a substantial part of metastatic NSCLC patients. 
Especially for oligometastatic NSCLC patients, this integration might be meaning-
ful due to a low tumor burden that seems to be one of the most important predictive 
factors for the benefit of SBRT-immunotherapy combination. In the future, further 
studies are needed to assess different treatment variables in order to optimize man-
agement of oligometastatic NSCLC in the way that the intent of treatment might 
not be just prolonged survival but cure.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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